Skip to main content
SpringerLink
Log in

IL-1α Enhancement of Platinum-Mediated Anti-Tumor Activity

  • Chapter
Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2

  • 81 Accesses

Abstract

Cytokines or biological response modifiers have been utilized in combination with conventional chemotherapeutic agents to increase cytotoxic drug-mediated efficacy and to reduce the associated toxic side effects. Interleukin-1 (IL-1) is a multifunctional cytokine, primarily produced by monocyte/macrophages1–4, that plays a central role in the activation of T and B cells3,4, potentiates hematopoiesis both in vitro and in vivo5–9, and induces the synthesis of other cytokines and regulatory molecules3,10,11. Studies in our laboratories have demonstrated that IL-1α induces acute tumor hemorrhagic necrosis, changes in tumor blood flow, an increase of tumor clonogenic cell kill and enhancement of cytotoxic drug-mediated anti-tumor effects in murine tumor model systems12–20. We focus our discussion here on IL-1’s activities in the treatment of solid tumors either alone or in combination with the platinum agents, cisplatin or carboplatin.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. I. Gery, R.K. Gershon, and B.H. Waksman, Potentiation of the T-lymphocyte response to mitogens: I. The responding cell, J. Exp. Med. 136:128 (1972).

    Article  CAS  PubMed  Google Scholar 

  2. C.A. Dinarello, Interleukin-1, Rev. Infect. Dis. 6:51 (1984).

    Article  CAS  PubMed  Google Scholar 

  3. J. Le, and J. Vilcek, Biology of disease: tumor necrosis factor and inter-leukin 1. Cytokines with multiple overlapping biological activities, Lab. Invest. 56:234 (1987).

    CAS  PubMed  Google Scholar 

  4. K.A. Smith, L.B. Lachman, J.J. Oppenheim, and M.J. Favata, The functional relationship of the interleukins, J. Exp. Med. 151:1551 (1980).

    Article  CAS  PubMed  Google Scholar 

  5. C.S. Johnson, DJ. Keckler, M.I. Topper, P.G. Braunschweiger, and P. Furmanski, In vivo hematopoietic effects of recombinant interleukin-1α in mice: stimulation of granulocytic, monocytic, megakaryocytic, and early erythroid progenitors, suppression of late-stage erythropoiesis, and reversal of erythroid suppression with erythropoietin. Blood 73:678 (1989).

    CAS  PubMed  Google Scholar 

  6. L.C. Stork, U.M. Peterson, C.H. Rundus, and W.A. Robinson, Interleukin-1 enhances murine granulopoiesis in vivo. Exp. Hematol. 16:163 (1988).

    CAS  PubMed  Google Scholar 

  7. M.A.S. Moore, and DJ. Warren, Synergy of interleukin 1 and granulocyte colony-stimulating factor: in vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice, Proc. Natl. Acad. Sci. 84:7134 (1987).

    Article  CAS  PubMed  Google Scholar 

  8. D.Y. Mochizuki, J.R. Eisenman, P.J. Conlon, A.D. Larsen, and R.J. Tushinski, Interleukin 1 regulates hematopoietic activity, a role previously ascribed to hemopoietin 1, Proc. Natl. Acad. Sci. 84:5267 (1987).

    Article  CAS  PubMed  Google Scholar 

  9. J.R. Zucali, H.E. Broxmeyer, C.A. Dinarello, M.A. Gross, and R.S. Weiner, Regulation of early human hematopoietic (BFU-E and CFU-GEMM) progenitor cells in vitro by interleukin-1-induced fibroblast-conditioned medium. Blood 69:33 (1987).

    CAS  PubMed  Google Scholar 

  10. R. Philip, and L.B. Epstein, Tumor necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature 323:86 (1986).

    Article  CAS  PubMed  Google Scholar 

  11. J.J. Oppenheim, E.J. Kovacs, K. Matsushima, and S.K. Durum, There is more than one interleukin 1. Immunol. Today 7:45 (1986).

    Article  CAS  Google Scholar 

  12. P.G. Braunschweiger, C.S. Johnson, N. Kumar, V. Rod and P. Furmanski, Antitumor effects of recombinant human interleukin-1α in RIF-1 and Panc02 solid tumors. Cancer Res. 48:6011 (1988).

    CAS  PubMed  Google Scholar 

  13. C.S. Johnson, M.-J. Chang, P.G. Braunschweiger and P. Furmanski, Acute hemorrhagic necrosis of tumor induced by interleukin-1α: effects independent of tumor necrosis factor, J. Natl. Cancer Inst. 12:842 (1990).

    Google Scholar 

  14. I. Constantinidis, P.G. Braunschweiger, J.P. Wehrle, N. Kumar, C.S. Johnson, P. Furmanski and J.D. Glickson, P-nuclear magnetic resonance studies of the effect of recombinant human interleukin-1α on the bioenergetics of RIF-1 tumors. Cancer Res. 49:6379 (1989).

    CAS  PubMed  Google Scholar 

  15. P.G. Braunschweiger, N. Kumar, I. Constantinidis, J.P. Wehrle, J.D. Glickson, C.S. Johnson and P. Furmanski, Potentiation of interleukin 1α mediated antitumor effects by ketoconazole. Cancer Res. 50:4709 (1990).

    CAS  PubMed  Google Scholar 

  16. P.G. Braunschweiger, C.S. Johnson, N. Kumar, V. Ord and P. Furmanski, The effect of adrenalectomy and dexamethasone on interleukin-1α induced responses in RIF-1 tumors, Br. tJ. Cancer 61:9 (1990).

    Article  CAS  Google Scholar 

  17. P.G. Braunschweiger, S.A. Jones, C.S. Johnson and P. Furmanski, Potentiation of mitomycin C and porfiromycin antitumor activity in solid tumor models by recombinant human interleukin 1. Cancer Res. 51:5454 (1991).

    CAS  PubMed  Google Scholar 

  18. C.S. Johnson, M.J. Chang, W.D. Yu, R.A. Modzelewski, J.R. Grandis, D.R. Vlock and P. Furmanski, Synergistic enhancement by interleukin-1 α of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice, Cancer Chemother. Pharmacol. 32:339 (1993).

    CAS  Google Scholar 

  19. C.S. Johnson, Interleukin-1: therapeutic potential for solid tumors. Cancer Invest. 11:600 (1993).

    Article  CAS  PubMed  Google Scholar 

  20. M.J. Chang, W.D. Yu, L.M. Reyno, R.A. Modzelewski, M.J. Egorin, K. Erkmen, D.R. Vlock, P. Furmanski and C.S. Johnson, Potentiation by interleukin 1α of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model. Cancer Res. 54:5380 (1994).

    CAS  PubMed  Google Scholar 

  21. M.P. Bevilacqua, J.S. Pober, G.R. Majeau, W. Fiers, R.S. Cotran, and M.A. Gimbron, Recombinant tumor necrosis factor induces precoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1, Proc. Natl. Acad. Sci. 83:4533 (1986).

    Article  CAS  PubMed  Google Scholar 

  22. T.H. Pohlman, K.A. Stanness, P.G. Beatty, H.D. Ochs, and J.M. Harlan, An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-alpha increases neutrophil adherence by a CDw 18-dependent mechanism. J. Immunol. 136:45 (1986).

    Google Scholar 

  23. R.L. Nachman, K.A. Hajjar, R.L. Silverstein, and C.A. Dinarello, Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor, J. Exp.Med. 163:1595(1986).

    Article  CAS  PubMed  Google Scholar 

  24. M. Gowen, and G.R. Mundy, Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone résorption in vitro. J. Immunol. 136:2478 (1986).

    CAS  PubMed  Google Scholar 

  25. J.E. Horton, L.G. Raisz, H.A. Simmons, J.J. Oppenheim, and S.E. Mergen-hagen, Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes. Science 177:793 (1972).

    Article  CAS  PubMed  Google Scholar 

  26. U. Barocos, H.P. Rodemann, C.A. Dinarello, and A.L. Goldberg, Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanisms for the increased degradation of muscle proteins during fever, N. Eng. J. Med. 308:553 (1983).

    Article  Google Scholar 

  27. G. Ramadori, J.D. Sipe, C.A. Dinarello, S.B. Mizel, and H.R. Colten, Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin 1 (IL-1) and purified human IL-1, J. Exp. Med. 162:930 (1985).

    Article  CAS  PubMed  Google Scholar 

  28. J.A. Schmidt, S.B. Mizel, D. Cohen, and I. Green, Interleukin 1, a potential regulator of fibroblast proliferation. J. Immunol. 128:2177 (1982).

    CAS  PubMed  Google Scholar 

  29. M. Gowen, D.D. Wood, and R.G. Russell, Stimulation of the proliferation of human bone cells in vitro by human monocyte products with interleukin-1 activity, J. Clin. iInvest. 75:1223 (1985).

    Article  CAS  Google Scholar 

  30. U. Ruggiero, and C. Baglioni, Synergistic anti-proliferative activity of interleukin 1 and tumor necrosis factor. J. Immunol. 138:661 (1987).

    CAS  PubMed  Google Scholar 

  31. F. Cozzolino, M. Torcia, D. Aldinucci, M. Ziehe, F. Almerigogna, D. Bani, and D.M. Stern, Interleukin 1 is an autocrine regulator of human endothelial cell growth, Proc. Natl. Acad. Sci. 87:6487 (1990).

    Article  CAS  PubMed  Google Scholar 

  32. C.J. March, B. Mosley, A. Larsen, D.P. Cerretti, G. Braedt, V. Price, S. Gillis, C.S. Henney, S.R. Kronheim, K. Grapstein, P.J. Conlon, T.P. Hopp and D. Cosman, Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 315:641 (1985).

    Article  CAS  PubMed  Google Scholar 

  33. E.V. Gaffney and S.C. Tsai, Lymphocyte-activating and growth-inhibitory activities for several sources of native and recombinant interleukin 1. Cancer Res. 46:3834 (1986).

    CAS  PubMed  Google Scholar 

  34. C.A. Dinarello, The interleukin-1 family: 10 years of discovery. FASEB 8:1314 (1994).

    CAS  Google Scholar 

  35. C.H. Hannum, C.J. Wilcox, W.P. Arend, F.G. Joslin, DJ. Dripps, P.L. Heimdal, L.G. Armes, A. Sommer, S.P. Eisenberg and R.C. Thompson, Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343:336 (1990).

    Article  CAS  PubMed  Google Scholar 

  36. D.B. Carter, M.R. Deibel, C.J. Dunn, C.S.C. Tomich, et al, Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 344:633 (1990).

    Article  CAS  PubMed  Google Scholar 

  37. C.A. Dinarello, Interleukin-1 and interleukin-1 antagonism. Blood 77:1627 (1991).

    CAS  PubMed  Google Scholar 

  38. D.J. Dripps, B.J. Brandhuber, R.C. Thompson, S.P. Eisenberg, Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction, J. Biol. Chem. 266:10331 (1991).

    CAS  PubMed  Google Scholar 

  39. J.R. Zucali, C.A. Dinarello, D.J. Oblon, M.A. Gross, L. Anderson, and R.S. Weiner, Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colony-stimulating activity and prostaglandin E2, J. Clin. iInvest. 77:1857 (1986).

    Article  CAS  Google Scholar 

  40. R. Neta, M.B. Sztein, J.J. Oppenheim, S. Gillis, and S.D. Douches, The in vivo effects of interleukin 1: I. bone marrow cells are induced by cycle after administration of interleukin 1, J. Immunol. 139:1861 (1987).

    CAS  PubMed  Google Scholar 

  41. R. Neta, S. Douches, and J.J. Oppenheim, Interleukin-1 is a radioprotector. J. Immunol. 136:2483 (1986).

    CAS  PubMed  Google Scholar 

  42. T.R. Bradley, N. Williams, A.B. Kriegler, J. Fawcett, and G.S. Hodgson, In vivo effects of interleukin-1α on regenerating mouse bone marrow myeloid colony-forming cells after treatment with 5-fluorouracil. Leukemia 3:893 (1989).

    CAS  PubMed  Google Scholar 

  43. M.A.S. Moore, R.L. Stolfi, and D.S. Martin, Hematologic effects of interleukin-1β, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor in tumor-bearing mice treated with fluorouracil, J. Natl. Cancer Inst. 82:1031 (1990).

    Article  CAS  PubMed  Google Scholar 

  44. J. Moreb and J.R. Zucali, Role of interleukin-1 in 4-hydroperoxy-cyclophosphamide toxicity to bone marrow progenitor cells: a review. Biotherapy 1:273 (1989).

    Article  CAS  PubMed  Google Scholar 

  45. M.A.S. Moore, R.L. Stolfi and D.S. Martin, Hematologic effects of interleukin-1β, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor in tumor-bearing mice treated with fluorouracil, J. Natl. Cancer Inst. 82:1031 (1990).

    Article  CAS  PubMed  Google Scholar 

  46. V. Rossi, F. Breviario, P. Ghezzi, E. Dejana, and A. Mantovani, Prostacyclin synthesis induced in vascular cells by interleukin-1. Science 229:174 (1985).

    Article  CAS  PubMed  Google Scholar 

  47. J.J. Emeis, and T. Kooistra, Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells, J. Exp. Med. 163:1260 (1986).

    Article  CAS  PubMed  Google Scholar 

  48. M.P. Bevilacqua, J.S. Pober, M.E. Wheeler, R.S. Cotran, and M.A. Gimbrone, Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines, J. Clin. iInvest. 76:2003 (1985).

    Article  CAS  Google Scholar 

  49. A.M. Lamas, CM. Mulroney, and R.P. Schleimer, Studies on the adhesive interaction between purified human eosinophils and cultured vascular endothelial cells. J. Immunol. 140:1500 (1988).

    CAS  PubMed  Google Scholar 

  50. E.A. Carswell, L.J. Old, R.L. Kassel, S. Green, N. Fiore, and B. Williamson, An endotoxin-induced serum factor that causes necrosis of tumors, Proc. Natl. Acad. Sci. 72:3666 (1975).

    Article  CAS  PubMed  Google Scholar 

  51. L.J. Old, Tumor necrosis factor (TNF). Science 230:630 (1985).

    Article  CAS  PubMed  Google Scholar 

  52. K. Tracey, B. Beutler, S. Lowry, J. Merryweather, S. Wolpe, I. Milsark, R. Hariri, T. Fahey, A. Zentella, J. Albert, G. Shired, and A. Cerami, Shock and tissue injury induced by recombinant human cachectin. Science 234:470 (1987).

    Article  Google Scholar 

  53. P.P. Nawroth, and D.M. Stern, Modulation of endothelial cell hemostatic properties by tumor necrosis factor, J. Exp. Med. 163:740 (1986).

    Article  CAS  PubMed  Google Scholar 

  54. P.P. Nawroth, D. Haudley, G. Matsulda, R. DeWall, H. Gerlach, D. Blohn, and D.M. Stern, Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas, J. Exp. Med. 168:637 (1988).

    Article  CAS  PubMed  Google Scholar 

  55. R.J. North, and E.A. Havell, The antitumor function of tumor necrosis factor (TNF) II. Analysis of the role of endogenous TNF in endotoxin-induced hemorrhagic necrosis and regression of an established sarcoma, J. Exp. Med. 167:1086 (1988).

    Article  CAS  PubMed  Google Scholar 

  56. H.F. Dvorak, and I. Gresser, Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice, J. Natl. Cancer Inst. 81:497 (1989).

    Article  CAS  PubMed  Google Scholar 

  57. F. Belardelli, E. Proietti, J. Ciolli, P. Sestili, G. Carpinelli, M. Divito, A. Ferretti, D. Woodrow, D. Boraschi, and F. Podo, Interleukin-1 beta induces tumor necrosis and early morphologic and metabolic changes in transplantable mouse tumors. Similarities with the anti-tumor effects of tumor necrosis factor alpha or beta, Int. J. Cancer 44:116 (1989).

    Article  CAS  PubMed  Google Scholar 

  58. E.A. Havell, W. Fiers, and R.J. North, The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity, J. Exp. Med. 167:1067 (1988).

    Article  CAS  PubMed  Google Scholar 

  59. P.L. Kilian, K.L. Kaffka, D.A. Biondi, J.M. Lipman, W.R. Benjamin, D. Feldman and C.A. Campen, Antiproliferative effect of interleukin-1 on human ovarian carcinoma cell line. Cancer Res. 51:1823 (1991).

    CAS  PubMed  Google Scholar 

  60. K. Onozaki, K. Matsushima, B.B. Aggarwal, and J.J. Oppenheim, Human interleukin-1 is a cytocidal factor for several tumor-cell lines. J. Immunol. 135:3962 (1985).

    CAS  PubMed  Google Scholar 

  61. L.B. Lachman, C.A. Dinarello, N.D. Llansa, I.J. Fidler, Natural and recombinant human interleukin-1β is cytotoxic for human melanoma cells. J. Immunol. 136:3098 (1986).

    CAS  PubMed  Google Scholar 

  62. R.J. North, R.H. Neubauer, J.J.H. Huang, R.C. Newton, and S.E. Loveless, Interleukin 1-induced, T cell-mediated regression of immunogenic murine tumors, J. Exp. Med. 168:2031 (1988).

    Article  CAS  PubMed  Google Scholar 

  63. M. Pezzella, M.E. Neville, J.J. Huang, In vivo inhibition of tumor growth of B16 melanoma by recombinant interleukin-1β: I. Tumor inhibition parallels lymphocyte activating factor activity of interleukin-1β proteins. Cytokine 2:357 (1990).

    Article  CAS  PubMed  Google Scholar 

  64. S. Nakamura, K. Nakata, S. Kashimoto, H. Yoshida, and M. Yamada, Antitumor effect of recombinant human interleukin 1 alpha against murine syngeneic tumors, Jpn. J. Cancer Res. 77:767 (1988).

    Google Scholar 

  65. K. Nakata, S. Kashimoto, H. Yoshida, T. Oku, and S. Nakamura, Augmented anti-tumor effect of recombinant human interleukin-1α by indomethacin. Cancer Res. 48:584 (1988).

    CAS  PubMed  Google Scholar 

  66. A. Tewari, W.C., Buhles Jr. and H.F. Starnes Jr, Preliminary report: effect of interleukin-1 on platelet counts, Lancet 336:712 (1990).

    Article  CAS  PubMed  Google Scholar 

  67. J.W. Smith, W.J. Urba, B.D. Curti, et al, The toxic and hematologic effects of interleukin-1α administered in a phase I trial to patients with advanced malignancies, J. Clin. Oncol. 10:1141 (1992).

    PubMed  Google Scholar 

  68. J. Crown, A. Jakubowski, N. Kemeny, et al, A phase I trial of recombinant human interleukin-1β alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. Blood 78:1420 (1991).

    CAS  PubMed  Google Scholar 

  69. J.W. Smith II, D.L. Longo, W.G. Alvord, J.E. Janik, et al, The effects of treatment with interleukin-la on platelet recovery after high-dose carboplatin, N. Engl. J. Med. 328:756.

    Google Scholar 

  70. J. Nemunaitis, F.R. Appelbaum, K. Lilleby, W.C. Buhles, C. Rosenfeld, Z.R. Zeigler, R.K. Shadduck, J.W. Singer, W. Meyer and C.D. Buckner, Phase I study of recombinant interleukin-1β in patients undergoing autologous bone marrow transplant for acute myelogenous leukemia. Blood 83:3473 (1994).

    CAS  PubMed  Google Scholar 

  71. D.R. Vlock, C.S. Johnson, M.-J. Chang, L.M. Reyno, K. Erkmen, M.J. Egorin, T. Logan and C. McCauley, Phase I trial of interleukin-1 alpha (IL-1) and carboplatin (CBDCA), Proc. Amer. Assoc. Cancer Res. 34:296 (1993).

    Google Scholar 

  72. T.F. Logan, H. Bishop, M.A. Mintun, Y. Choi, D. Sashin, M.A. Virji, T. Billiar, D.L. Trump, D. Smith, J.M. Kirkwood, D.R. Vlock, M.-J. Chang, M.J. Egorin and C.S. Johnson, Phase I trial of interleukin-la and carboplatin in patients with metastatic disease to the lung: effects on tumor blood flow evaluated by positron emission tomography, Proc. Amer. Assoc. Cancer Res. 35:198 (1994).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Otolaryngology, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213, USA

    Candace S. Johnson, Ming-Jei Chang, Wei-Dong Yu, Ruth A. Modzelewski & Derick M. Russell

  2. Department of Pharmacology, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213, USA

    Candace S. Johnson

  3. Department of Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213, USA

    Theodore F. Logan

  4. Brigham and Women’s Hospital, Boston, MA, 02115, USA

    Daniel R. Vlock

  5. Department of Medicine, Division of Hematology-Oncology, University of Maryland School of Medicine, University of Maryland Cancer Center, Baltimore, MD, 21201, USA

    Leonard M. Reyno, Merrill J. Egorin & Kadir Erkmen

  6. Department of Biology, New York University, New York, NY, 10003, USA

    Philip Furmanski

Authors
  1. Candace S. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ming-Jei Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wei-Dong Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ruth A. Modzelewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Derick M. Russell
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Theodore F. Logan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Daniel R. Vlock
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Leonard M. Reyno
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Merrill J. Egorin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kadir Erkmen
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Philip Furmanski
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Free University, Amsterdam, The Netherlands

    H. M. Pinedo

  2. Netherlands Cancer Institute, Amsterdam, The Netherlands

    J. H. Schornagel

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer Science+Business Media New York

About this chapter

Cite this chapter

Johnson, C.S. et al. (1996). IL-1α Enhancement of Platinum-Mediated Anti-Tumor Activity. In: Pinedo, H.M., Schornagel, J.H. (eds) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0218-4_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-4899-0218-4_23

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4899-0220-7

  • Online ISBN: 978-1-4899-0218-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation